Illimis Therapeutics
Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimer’s. Our platform is differentiated by its ability to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from existing antibody drugs that utilize FcR-mediated phagocytosis of microglia, by utilizing TAM receptor, a novel phagocytic receptor expressed on the surface of glial cells.
7-day free trial · no credit card
Verified contacts
19
available on Kipplo
LinkedIn employees
25
11 to 50 range
Open roles
—
no listings
Distinct roles
14
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 19 verified contacts at Illimis Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
19 contacts with verified email or phone · masked until revealed.
- JL
Jin Lee
Vice President · General Business & Management
EmailPhone - JL
Juho Lee
Project Leader · Research & Development
EmailPhone
Showing 2 of 19 verified contacts
Top roles at Illimis Therapeutics
14 distinct titles indexed · top 10 shown.
- 3manager
- 2cmc group leader
- 2포항공과대학교
- 1advisory board
- 1business & strategy team team leader
- 1cfo & coo
- 1head of management group
- 1head of r & d strategy
- 1manager(part leader)
- 1people planning & ta team leader
- +4more titles
Sign up to unlock all 19 contacts at Illimis Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 19 verified contacts at Illimis Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.